Karen Dineen Wagner, MD, PhD: Management of Treatment Refractory Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

Name: Karen Dineen Wagner, MD, PhD: Management of Treatment Refractory Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
SKU: 3260
Price: 30.00 USD
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 36 No. 1 Articles Tags: bupropion, clonidine, dextroamphetamine, guanfacine, karen-dineen-wagner, medworks-media, methylphenidate, psychopharmacology-bulletin, psychostimulant, tricyclic-antidepressant

Description

Karen Dineen Wagner, MD, PhD: Management of Treatment Refractory Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

Description

Karen Dineen Wagner, MD, PhD

GENERAL PSYCHOPHARMACOLOGY

Management of Treatment Refractory Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

Karen Dineen Wagner, MD, PhD

Clozapine Factors in Schizophrenia by Takefumi Suzuki

Quetiapine XR Negative Clinical Trials Report by Gang Wang

What Mood Symptoms may be most Difficult to Rate?

Assessment of Anxiety in Clinical Trials with Depressed Patients

Karen Dineen Wagner, MD, PhD: Management of Treatment Refractory Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

Description

Karen Dineen Wagner, MD, PhD

GENERAL PSYCHOPHARMACOLOGY

Management of Treatment Refractory Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

Karen Dineen Wagner, MD, PhD

Related products

Clozapine Factors in Schizophrenia by Takefumi Suzuki

Quetiapine XR Negative Clinical Trials Report by Gang Wang

What Mood Symptoms may be most Difficult to Rate?

Assessment of Anxiety in Clinical Trials with Depressed Patients